Cancer is not a risk factor for severe COVID-19 in children, except in
patients with recent allogeneic hematopoietic stem cell transplantion
recipients or comorbidities.
Abstract
The EPICO-SEHOP platform gathers data from children with SARS-CoV-2 in
Spain, allowing comparison between children with cancer or allogeneic
hematopoietic stem cell transplantation (alloHSCT) and those without.
The infection is milder in the cancer/alloHSCT group than in children
without comorbidities (7.1% vs. 15%), except in children with recent
alloHSCT (less than 300 days), of which 35.7% experienced severe
COVID-19. These data have been shared with the SEHOP members to support
treatment and isolation policies akin to those for children without
cancer, except for those with recent alloHSCT or additional
comorbidities. This highlights the collaborative registries potential in
managing pandemic emergencies.